Eli Lilly and Firm introduced detailed outcomes from ACHIEVE-1, a Section 3 trial evaluating the protection and efficacy of orforglipron in comparison with placebo in adults with sort 2 diabetes and insufficient glycemic management with weight-reduction plan and train alone. Orforglipron is the primary oral small molecule (non-peptide) glucagon-like peptide-1 (GLP-1) receptor agonist, taken with out meals and water restrictions, to efficiently full a Section 3 trial. At 40 weeks, all three doses (3 mg, 12 mg, 36 mg) of orforglipron achieved the first endpoint of superior A1C discount. As well as, the 12 mg and 36 mg doses confirmed clinically significant and statistically vital reductions in physique weight vs. placebo. Within the research, orforglipron had a security profile just like the established GLP-1 class, and probably the most regularly reported opposed occasions have been gastrointestinal-related. The outcomes have been offered on the American Diabetes Affiliation (ADA) 85th Scientific Periods 2025
Within the research, orforglipron met the first endpoint of superior A1C discount in comparison with placebo at 40 weeks, reducing A1C by 1.3% to 1.6% from a baseline of 8.0%, for the efficacy estimand.1 In key secondary endpoints, as much as 76.2% of members taking orforglipron achieved the ADA remedy goal A1C of two,3 Enhancements in A1C have been noticed as early as 4 weeks and have been accompanied by related reductions in fasting serum glucose. In one other key secondary endpoint, members taking the best dose of orforglipron misplaced a mean of 16.0 lbs (7.9%). Whereas members in ACHIEVE-1 didn’t seem to succeed in a weight plateau, longer-duration trials, such because the ATTAIN trials, will present a complete analysis of the protection and efficacy of orforglipron for the remedy of weight problems.
“The ACHIEVE-1 trial demonstrated that orforglipron, a novel oral small-molecule GLP-1, achieved clinically significant reductions in A1C and physique weight over 40 weeks in adults with sort 2 diabetes,” mentioned Dr. Julio Rosenstock, senior scientific advisor for Velocity Medical Analysis at Medical Metropolis Dallas, and scientific professor of medication, College of Texas Southwestern Medical Heart, and lead trial investigator. “The early onset of glycemic enchancment, noticed as quickly as 4 weeks, reinforces the therapeutic potential of orforglipron as an efficient, oral GLP-1 remedy for early sort 2 diabetes remedy. These findings help additional investigation in broader populations and longer-duration research.”
| Full Outcomes | |||||
| Orforglipron 3 mg | Orforglipron 12 mg | Orforglipron 36 mg | Placebo | ||
| Main Endpoint | |||||
| A1C discount from baseline of 8.0%i | Efficacy estimand | 1.3% | 1.6% | 1.5% | 0.1% |
| Therapy-regimen estimand4 | 1.2% | 1.5% | 1.5% | 0.4% | |
| Key Secondary Endpointsii | |||||
| % weight discount from baseline of 90.2 kg (198.9 lbs)i, iii | Efficacy estimand | 4.7% | 6.1% | 7.9% | 1.6% |
| Therapy-regimen estimand | 4.5% | 5.8% | 7.6% | 1.7% | |
| Weight discount from baseline of 90.2 kg (198.9 lbs)i,iii | Efficacy estimand | 4.4 kg (9.7 lbs) |
5.5 kg (12.2 lbs) |
7.3 kg (16.0 lbs) |
1.3 kg (2.9 lbs) |
| Therapy-regimen estimand | 4.2 kg (9.3 lbs) | 5.2 kg (11.5 lbs) | 7.2 kg (15.8 lbs) | 1.5 kg (3.4 lbs) | |
| % of members attaining A1C i | Efficacy estimand | 72.9% | 76.2% | 74.9% | 28.0% |
| Therapy-regimen estimand | 68.1% | 72.9% | 72.7% | 33.0% | |
| % of members attaining A1C ≤6.5%i, ii | Efficacy estimand | 61.5% | 62.3% | 66.0% | 13.5% |
| Therapy-regimen estimand | 56.9% | 58.1% | 61.9% | 14.9% | |
| % of members attaining A1C iii | Efficacy estimand | 17.7% | 25.8% | 23.9% | 3.8% |
| Therapy-regimen estimand | 16.8% | 23.9% | 21.5% | 3.8% | |
| Fasting serum glucose discount from baseline of 147.5 mg/dLi | Efficacy estimand | 30.6 mg/dL | 37.4 mg/dL | 37.8 mg/dL | 1.1 mg/dL |
| Therapy-regimen estimand | 30.7 mg/dL | 36.5 mg/dL | 34.7 mg/dL | 10.8 mg/dL | |
iSuperiority take a look at was adjusted for multiplicity.
iiKnowledge from the total record of key secondary endpoints can be found within the publication.
iii% of members attaining A1C
“This handy once-daily tablet with no restrictions on meals and water consumption might be an choice for tens of millions of individuals with sort 2 diabetes preferring oral drugs over injectables,” mentioned Jeff Emmick, MD, Ph.D., senior vp of product growth at Lilly. “The constructive ACHIEVE-1 outcomes place orforglipron as a possible remedy choice with significant A1C and weight discount, and a security profile just like injectable GLP-1 therapies. We stay up for the 4 remaining world readouts from the ACHIEVE program, in addition to outcomes of the ATTAIN program in weight problems, and dealing with regulators to carry this once-daily oral GLP-1 to folks around the globe.”
The general security profile of orforglipron in ACHIEVE-1 was in step with the established GLP-1 class. The most typical opposed occasions for members handled with orforglipron (3 mg, 12 mg and 36 mg, respectively) have been diarrhea (19%, 21% and 26%) vs. 9% with placebo, nausea (13%, 18% and 16%) vs. 2% with placebo, dyspepsia (11%, 20% and 15%) vs. 7% with placebo, constipation (8%, 17% and 14%) vs. 4% with placebo, and vomiting (5%, 7% and 14%) vs. 1% with placebo. These gastrointestinal-related opposed occasions have been usually mild-to-moderate in severity, and occurred primarily throughout dose escalation. Total remedy discontinuation charges on account of opposed occasions have been 6% (3 mg), 4% (12 mg) and eight% (36 mg) for orforglipron vs. 1% with placebo. No hepatic security sign was noticed.
Later this yr, Lilly expects to share topline outcomes from ACHIEVE-2, evaluating orforglipron in contrast with dapagliflozin, and ACHIEVE-3, evaluating orforglipron in comparison with oral semaglutide, each in adults with sort 2 diabetes inadequately managed with metformin. ATTAIN-1 and ATTAIN-2, evaluating orforglipron for weight administration, can even be shared within the third quarter of this yr. Lilly stays on monitor to submit orforglipron for weight administration to world regulatory companies by the tip of this yr and for the remedy of sort 2 diabetes in 2026.